IRB #

STUDY00019661

Title

[NCI CIRB] EA8143 (PROSPER): A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare recurrence-free survival (RFS) between patients with locally advanced renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial
nephrectomy with patients randomized to surgery alone.

Medical Condition(s)

advanced renal cell carcinoma

Eligibility Criteria

Eligibility criteria highlighted below:

1- Diagnosis of renal mass per protocol section 3.1.1
2-

A complete list of the eligibility criteria can be found in section 3.0 of the protocol.

Age Range

18 - 110

Healthy Volunteers Needed

No

Duration of Participation

10 years from the time of study entry.

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

ECOG - ACRIN

Recruitment End

03/31/2023

Compensation Provided

No


Go Back